Zyvox

Zyvox is a brand name of linezolid, approved by the FDA in the following formulation(s):

ZYVOX (linezolid - for suspension; oral)

• 
  Manufacturer: PHARMACIA AND UPJOHN
  
  Approval date: April 18, 2000
  
  Strength(s): 100MG/5ML ^[RLD]

ZYVOX (linezolid - injectable; injection)

• 
  Manufacturer: PHARMACIA AND UPJOHN
  
  Approval date: April 18, 2000
  
  Strength(s): 200MG/100ML ^[RLD]

ZYVOX (linezolid - tablet; oral)

• 
  Manufacturer: PHARMACIA AND UPJOHN
  
  Approval date: April 18, 2000
  
  Strength(s): 600MG ^[RLD]

Has a generic version of Zyvox been approved?

No. There is currently no therapeutically equivalent version of Zyvox available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zyvox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Substituted oxazine and thiazine oxazolidinone antimicrobials
  Patent 5,688,792
  Issued: November 18, 1997
  Inventor(s): Barbachyn; Michael R. & Brickner; Steven J. & Hutchinson; Douglas K.
  Assignee(s): Pharmacia & Upjohn Company
  A compound of structural Formula I: ##STR1## or pharmaceutically acceptable salts thereof wherein: X is O, S, SO, SO.sub.2, SNR.sup.10 or S(O)NR.sup.10 ; R is (a) hydrogen, (b) C.sub.1 -C.sub.8 alkyl optionally substituted with one or more of the following: F, Cl, hydroxy, C.sub.1 -C.sub.8 alkoxy, C.sub.1 -C.sub.8 acyloxy or --O--CH.sub.2 --Ph, (c) C.sub.3 -C.sub.6 cycloalkyl, (d) amino, (e) C.sub.1 -C.sub.8 alkylamino, (f) C.sub.1 -C.sub.8 dialkylamino or (g) C.sub.1 -C.sub.8 alkoxy; R.sup.1 is H, except when X is O then R.sup.1 can be H, CH.sub.3, CN, CO.sub.2 H, CO.sub.2 R or (CH.sub.2).sub.m R.sup.11 (m is 1 or 2); R.sup.2 is independently H, F or Cl; R.sup.3 is H except when X is O and R.sup.1 is CH.sub.3 then R.sup.3 can be H or CH.sub.3 ; R.sup.10 is independently H, C.sub.1 -C.sub.4 alkyl (optionally substituted with chloro, fluoro, hydroxy, C.sub.1 -C.sub.8 alkoxy, amino, C.sub.1 -C.sub.8 alkylamino, or C.sub.1 -C.sub.8 dialkylamino) or p-toluenesulfonyl; R.sup.11 is hydrogen, OH, OR, OCOR, NH.sub.2, NHCOR or N(R.sup.10).sub.2 ; and n is 0, 1 or 2. The oxazine and thiazine oxazolidinone derivatives are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.
  
  Patent expiration dates:
  
  
  • November 18, 2014
    
    ✓ 
    Patent use: TREATMENT OF MICROBIAL INFECTIONS
    ✓ 
    Drug substance
  
  
  
  • November 18, 2014
    
    ✓ 
    Patent use: TREATMENT OF MICROBIAL INFECTIONS
  
  
  
  • May 18, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Oxazolidinone tablet formulation
  Patent 6,514,529
  Issued: February 4, 2003
  Inventor(s): Ken; Yamamoto & Homer; Lin
  Assignee(s): Pharmacia & Upjohn Company
  The present invention provides a compressed tablet of an antibacterial oxazolidinone agent which provides high drug load and excellent bioavailability.
  
  Patent expiration dates:
  
  
  • March 15, 2021
    
    ✓ 
    Drug product
  
  
  
  • September 15, 2021
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Linezolid—crystal form II
  Patent 6,559,305
  Issued: May 6, 2003
  Inventor(s): Michael S.; Bergren
  Assignee(s): Pharmacia & Upjohn Company
  The invention is a novel crystal form (Form II) of a known compound, linezolid which is useful as an antibacterial agent.
  
  Patent expiration dates:
  
  
  • January 29, 2021
    
    ✓ 
    Drug substance
  
  
  
  • July 29, 2021
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Zyvox Consumer Information (Drugs.com)
• Zyvox Consumer Information (Wolters Kluwer)
• Zyvox Suspension Consumer Information (Wolters Kluwer)
• Zyvox Tablets Consumer Information (Wolters Kluwer)
• Zyvox Consumer Information (Cerner Multum)
• Zyvox Advanced Consumer Information (Micromedex)
• Zyvox AHFS DI Monographs (ASHP)
• Linezolid Consumer Information (Wolters Kluwer)
• Linezolid Suspension Consumer Information (Wolters Kluwer)
• Linezolid Tablets Consumer Information (Wolters Kluwer)
• Linezolid Consumer Information (Cerner Multum)
• Linezolid Intravenous, Oral Advanced Consumer Information (Micromedex)
• Linezolid AHFS DI Monographs (ASHP)